The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.

The addition of concurrent cisplatin to adjuvant radiation therapy conferred no benefit to women with intermediate-risk, ...

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

The study looked at patients with leukaemia, which occurs in bone marrow, and lymphoma, which affects the lymphatic system.

Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus ...

In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed ...

Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma.